Pesquisar
Celcuity Inc
CELCAdicionar à lista de desejos
124.470USD
-0.210-0.17%
Fechamento 05/13, 16:00（ET）Cotações atrasadas em 15 min
6.02BValor de mercado
PerdaP/L TTM
Mais detalhes de Celcuity Inc Empresa
Celcuity Inc. is a clinical-stage biotechnology company, which develops targeted therapies for the treatment of multiple solid tumor indications. Its lead therapeutic candidate is gedatolisib, a potent, small-molecule reversible inhibitor that selectively targets all Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2. Its development programs for gedatolisib focus on the treatment of patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-), or HR+/HER2-, advanced or metastatic breast cancer and patients with metastatic castration resistant prostate cancer. A Phase III clinical trial of VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast has commenced. Its CELsignia companion diagnostic platform is able to analyze live patient tumor cells.
Informações de Celcuity Inc
Código da empresaCELC
Nome da EmpresaCelcuity Inc
Data de listagemSep 20, 2017
CEOSullivan (Brian F)
Número de funcionários87
Tipo de títulosOrdinary Share
Fim do ano fiscalSep 20
Endereço16305 36th Ave N Ste 100
CidadeMINNEAPOLIS
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal55446-4285
Telefone17633920767
Sitehttps://www.celcuity.com/
Código da empresaCELC
Data de listagemSep 20, 2017
CEOSullivan (Brian F)
Executivos da empresa Celcuity Inc
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Brian F. Sullivan
Mr. Brian F. Sullivan
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
3.12M
--
Mr. Richard J. Nigon
Mr. Richard J. Nigon
Independent Director
Independent Director
79.03K
-12.65%
Ms. Vicky Hahne, CPA
Ms. Vicky Hahne, CPA
Chief Financial Officer
Chief Financial Officer
19.81K
+4.79%
Dr. Richard E. Buller, M.D., Ph.D.
Dr. Richard E. Buller, M.D., Ph.D.
Independent Director
Independent Director
7.79K
+1.01%
Dr. Polly A. Murphy, DVM, Ph.D.
Dr. Polly A. Murphy, DVM, Ph.D.
Independent Director
Independent Director
5.00K
--
Dr. Lance G. Laing, Ph.D.
Dr. Lance G. Laing, Ph.D.
Co-Founder, Chief Science Officer, Vice President, Secretary, Director
Co-Founder, Chief Science Officer, Vice President, Secretary, Director
--
--
Mr. David F. Dalvey
Mr. David F. Dalvey
Independent Director
Independent Director
--
--
Dr. Leo T. Furcht, M.D.
Dr. Leo T. Furcht, M.D.
Independent Director
Independent Director
--
--
Dr. Charlotte Moser, M.D., Ph.D.
Dr. Charlotte Moser, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Brian F. Sullivan
Mr. Brian F. Sullivan
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
3.12M
--
Mr. Richard J. Nigon
Mr. Richard J. Nigon
Independent Director
Independent Director
79.03K
-12.65%
Ms. Vicky Hahne, CPA
Ms. Vicky Hahne, CPA
Chief Financial Officer
Chief Financial Officer
19.81K
+4.79%
Dr. Richard E. Buller, M.D., Ph.D.
Dr. Richard E. Buller, M.D., Ph.D.
Independent Director
Independent Director
7.79K
+1.01%
Dr. Polly A. Murphy, DVM, Ph.D.
Dr. Polly A. Murphy, DVM, Ph.D.
Independent Director
Independent Director
5.00K
--
Dr. Lance G. Laing, Ph.D.
Dr. Lance G. Laing, Ph.D.
Co-Founder, Chief Science Officer, Vice President, Secretary, Director
Co-Founder, Chief Science Officer, Vice President, Secretary, Director
--
--
Detalhamento da receita
Os dados relevantes ainda não foram divulgados pela empresa.
Os dados relevantes ainda não foram divulgados pela empresa.
Por Empresa
Por Região
Os dados relevantes ainda não foram divulgados pela empresa.
Distribuição de ações
Atualizado em: dom, 10 de mai
Atualizado em: dom, 10 de mai
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Baker Bros. Advisors LP
16.38%
Perceptive Advisors LLC
6.54%
Sullivan (Brian F)
6.46%
Avoro Capital Advisors LLC
6.44%
New Enterprise Associates (NEA)
4.73%
Outro
59.46%
Investidores
Investidores
Proporção
Baker Bros. Advisors LP
16.38%
Perceptive Advisors LLC
6.54%
Sullivan (Brian F)
6.46%
Avoro Capital Advisors LLC
6.44%
New Enterprise Associates (NEA)
4.73%
Outro
59.46%
Tipos de investidores
Investidores
Proporção
Hedge Fund
33.92%
Investment Advisor
23.78%
Investment Advisor/Hedge Fund
19.70%
Individual Investor
9.48%
Private Equity
6.96%
Research Firm
6.38%
Venture Capital
5.38%
Pension Fund
1.13%
Corporation
0.72%
Participação acionária institucional
Atualizado em: qua, 1 de abr
Atualizado em: qua, 1 de abr
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2026Q1
415
47.21M
97.67%
+1.59M
2025Q4
299
39.79M
87.00%
+296.61K
2025Q3
298
39.50M
98.78%
+3.79M
2025Q2
215
31.87M
95.31%
+797.76K
2025Q1
207
31.06M
92.46%
-3.93M
2024Q4
197
30.50M
91.70%
-18.57K
2024Q3
181
30.14M
86.73%
+764.96K
2024Q2
164
29.36M
68.66%
+7.16M
2024Q1
155
22.20M
60.61%
+3.55M
2023Q4
137
16.81M
74.10%
+667.49K
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Baker Bros. Advisors LP
7.92M
16.38%
--
--
Mar 20, 2026
Perceptive Advisors LLC
3.16M
6.54%
+203.88K
+6.90%
Dec 31, 2025
Sullivan (Brian F)
3.12M
6.46%
+96.19K
+3.18%
Sep 30, 2025
Avoro Capital Advisors LLC
3.11M
6.44%
+3.11M
--
Dec 31, 2025
New Enterprise Associates (NEA)
2.29M
4.73%
-625.00K
-21.47%
Mar 06, 2026
BlackRock Institutional Trust Company, N.A.
2.24M
4.64%
+199.90K
+9.78%
Dec 31, 2025
Soleus Capital Management, L.P.
1.81M
3.74%
+629.40K
+53.39%
Dec 31, 2025
Deerfield Management Company, L.P.
1.71M
3.55%
+980.47K
+133.66%
Dec 31, 2025
State Street Investment Management (US)
1.64M
3.39%
+914.89K
+126.58%
Dec 31, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 6 de dez
Atualizado em: sáb, 6 de dez
Nome
Proporção
iShares Genomics Immunology and Healthcare ETF
5.06%
Virtus LifeSci Biotech Clinical Trials ETF
4.16%
Tema Oncology ETF
3.44%
Invesco Dorsey Wright Healthcare Momentum ETF
3.35%
ALPS Medical Breakthroughs ETF
1.34%
Invesco Dorsey Wright SmallCap Momentum ETF
0.89%
iShares Micro-Cap ETF
0.44%
VictoryShares US Small Mid Cap Value Momentum ETF
0.26%
Vanguard US Momentum Factor ETF
0.16%
State Street SPDR S&P Biotech ETF
0.15%
Ver Mais
iShares Genomics Immunology and Healthcare ETF
Proporção5.06%
Virtus LifeSci Biotech Clinical Trials ETF
Proporção4.16%
Tema Oncology ETF
Proporção3.44%
Invesco Dorsey Wright Healthcare Momentum ETF
Proporção3.35%
ALPS Medical Breakthroughs ETF
Proporção1.34%
Invesco Dorsey Wright SmallCap Momentum ETF
Proporção0.89%
iShares Micro-Cap ETF
Proporção0.44%
VictoryShares US Small Mid Cap Value Momentum ETF
Proporção0.26%
Vanguard US Momentum Factor ETF
Proporção0.16%
State Street SPDR S&P Biotech ETF
Proporção0.15%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Data ex-dividendo
Tipo
Proporção
Sem dados
Data
Data ex-dividendo
Tipo
Proporção
Sem dados
